Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
about
Overview and recent advances in the treatment of neuroblastoma.Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma
P2860
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Outcome of children with relap ...... pean phase II clinical trials.
@en
Outcome of children with relap ...... pean phase II clinical trials.
@nl
type
label
Outcome of children with relap ...... pean phase II clinical trials.
@en
Outcome of children with relap ...... pean phase II clinical trials.
@nl
prefLabel
Outcome of children with relap ...... pean phase II clinical trials.
@en
Outcome of children with relap ...... pean phase II clinical trials.
@nl
P2093
P2860
P356
P1476
Outcome of children with relap ...... pean phase II clinical trials.
@en
P2093
Amalia Varo
Andrew D J Pearson
Aurelie Chevance
Birgit Geoerger
Francisco Bautista
Gilles Vassal
Herve Rubie
Loredana Amoroso
Lucas Moreno
Marie Cecile Le Deley
P2860
P356
10.1002/PBC.26192
P577
2016-08-24T00:00:00Z